Schwartzberg, L., McIntyre, K., Wilks, S., Puhalla, S., O’Shaughnessy, J., Berrak, E., . . . Vahdat, L. (2019). Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer. BMC Cancer.
Citação norma ChicagoSchwartzberg, Lee, Kristi McIntyre, Sharon Wilks, Shannon Puhalla, Joyce O’Shaughnessy, Erhan Berrak, Yaohua He, and Linda Vahdat. "Health-related Quality of Life in Patients Receiving First-line Eribulin Mesylate With or Without Trastuzumab for Locally Recurrent or Metastatic Breast Cancer." BMC Cancer 2019.
Citação norma MLASchwartzberg, Lee, et al. "Health-related Quality of Life in Patients Receiving First-line Eribulin Mesylate With or Without Trastuzumab for Locally Recurrent or Metastatic Breast Cancer." BMC Cancer 2019.